SCHEMBL5086114

SCHEMBL5086114

CCC(COCP(=O)(O)O)n1cnc2c(NC(c3ccccc3)(c3ccccc3)c3ccccc3OC)ncnc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 1/20 0.37
CCNB2 O95067 4/20 0.35
CDK1 P06493 4/20 0.35
CCNB1 P14635 4/20 0.35
CCNB3 Q8WWL7 4/20 0.35
CDK2 P24941 5/20 0.35
MAPK1 P28482 2/20 0.33
NT5E P21589 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
MITF O75030 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CCNE1 P24864 3/20 0.33
P2RY1 P47900 2/20 0.33
MAPK8 P45983 1/20 0.33
CSNK1A1 P48729 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14175387 0.89 CCNB2 (0.41) HPRT1CCNB2CDK1CCNB1CCNB3
SCHEMBL5083697 0.87 CCNB2 (0.39) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL5083559 0.82 CDK1 (0.35) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL14175384 0.81 CCNB2 (0.42) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL14175382 0.80 CDK1 (0.41) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL14175372 0.77 CCNB2 (0.42) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL14175378 0.74 CCNB2 (0.46) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL14175369 0.74 CDK1 (0.40) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL14175374 0.73 CCNB2 (0.40) CCNB2CDK1CCNB1CCNB3CDK2
SCHEMBL5086138 0.73 HPRT1 (0.44) HPRT1CCNB2CDK1CCNB1CCNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7388002-B2 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2008-06-17 US disclosed
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases POLR2H, NSUN2, POLR2E HPRT1 319/4885CCNB2 428/4885CDK1 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.